SOADOR
ENTA icon

State of Alaska Department of Revenue’s Enanta Pharmaceuticals ENTA Stock Holding History

State of Alaska Department of Revenue’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,017
Closed -$278K – 1618
2023
Q2 		$278K Sell
13,017
-427
-3% -$12.6K ﹤0.01% 1556
2023
Q1 		$543K Sell
13,444
-124
-0.9% -$5.92K 0.01% 1324
2022
Q4 		$631K Buy
13,568
+80
+0.6% +$3.65K 0.01% 1237
2022
Q3 		$699K Sell
13,488
-457
-3% -$26.7K 0.01% 1118
2022
Q2 		$659K Buy
13,945
+1,250
+10% +$67.8K 0.01% 1209
2022
Q1 		$903K Sell
12,695
-45
-0.4% -$2.93K 0.01% 1086
2021
Q4 		$952K Sell
12,740
-385
-3% -$30.2K 0.01% 1116
2021
Q3 		$745K Buy
13,125
+690
+6% +$34.1K 0.01% 1263
2021
Q2 		$547K Buy
12,435
+282
+2% +$13.8K 0.01% 1407
2021
Q1 		$599K Sell
12,153
-1,750
-13% -$87.3K 0.01% 1337
2020
Q4 		$585K Sell
13,903
-2,800
-17% -$123K 0.01% 1273
2020
Q3 		$764K Buy
16,703
+1,420
+9% +$68.8K 0.01% 1017
2020
Q2 		$767K Buy
15,283
+460
+3% +$23.8K 0.01% 1021
2020
Q1 		$762K Buy
14,823
+2,755
+23% +$147K 0.01% 891
2019
Q4 		$745K Sell
12,068
-181
-1% -$11.2K 0.01% 1079
2019
Q3 		$735K Buy
12,249
+6,827
+126% +$507K 0.01% 1060
2019
Q2 		$457K Buy
5,422
+115
+2% +$10.3K 0.01% 1106
2019
Q1 		$506K Buy
5,307
+25
+0.5% +$2.24K 0.01% 1052
2018
Q4 		$374K Buy
5,282
+200
+4% +$15.3K 0.01% 1128
2018
Q3 		$434K Buy
5,082
+352
+7% +$35.3K 0.01% 1192
2018
Q2 		$548K Buy
4,730
+90
+2% +$8.98K 0.01% 1022
2018
Q1 		$375K Buy
4,640
+1,800
+63% +$139K 0.01% 1124
2017
Q4 		$166K Buy
2,840
+90
+3% +$4.51K ﹤0.01% 1362
2017
Q3 		$128K Buy
2,750
+20
+0.7% +$804 0.01% 1124
2017
Q2 		$98K Buy
2,730
+1,190
+77% +$38.1K 0.01% 1111
2017
Q1 		$47K Buy
1,540
+40
+3% +$1.25K ﹤0.01% 1128
2016
Q4 		$50K Buy
+1,500
New +$43K ﹤0.01% 836

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State of Alaska Department of Revenue's ENTA Position: Q3 2023 in Review

State of Alaska Department of Revenue sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 13,017 shares — an estimated $278K sold.

State of Alaska Department of Revenue first reported a position in ENTA in Q4 2016 and held it in 27 quarters. The position peaked at $952K in Q4 2021. 133 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • State of Alaska Department of Revenue reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • State of Alaska Department of Revenue sold 13,017 Enanta Pharmaceuticals shares in Q3 2023, an estimated $278K.
  • State of Alaska Department of Revenue first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 27 quarters.
  • State of Alaska Department of Revenue's Enanta Pharmaceuticals position peaked at $952K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on State of Alaska Department of Revenue's 13F filing for Q3 2023, filed 16 Oct 2023.